Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F10%3A10215602" target="_blank" >RIV/61989592:15110/10:10215602 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment.

Popis výsledku v původním jazyce

In order to analyze the impact of IPL measurement on treatment results we have introduced the determination of IPL into our laboratory follow-up of CML patients in 2007. IPL were measured by UHPLC-TMS. 553 samples from 112 patients with CML treated at least 18 months and between 24?6 hours after the ingestion were used for statistics. We did not found correlation between IPL and probability of achievement of optimal cytogenetic or molecular response. We found high IPL inter-individual (394-3133 mg/l) and intra-individual variability (14.2-43.3%). In two patients with low IPL dose escalation led to IPL increase and improvement of treatment response. We were not able to demonstrate a clear correlation between IPL and response to imatinib therapy in our group of patients with CML. On the other hand in selected patients with low IPL and suboptimal response we were able to demonstrate that escalation of imatinib dose lead to optimal treatment response.

Název v anglickém jazyce

Measurement of trough imatinib plasma levels in patients with CML does not significantly correlate with treatment response but may be succesfully used in selected patients for dosage adjustment.

Popis výsledku anglicky

In order to analyze the impact of IPL measurement on treatment results we have introduced the determination of IPL into our laboratory follow-up of CML patients in 2007. IPL were measured by UHPLC-TMS. 553 samples from 112 patients with CML treated at least 18 months and between 24?6 hours after the ingestion were used for statistics. We did not found correlation between IPL and probability of achievement of optimal cytogenetic or molecular response. We found high IPL inter-individual (394-3133 mg/l) and intra-individual variability (14.2-43.3%). In two patients with low IPL dose escalation led to IPL increase and improvement of treatment response. We were not able to demonstrate a clear correlation between IPL and response to imatinib therapy in our group of patients with CML. On the other hand in selected patients with low IPL and suboptimal response we were able to demonstrate that escalation of imatinib dose lead to optimal treatment response.

Druh

D - Stať ve sborníku

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2010

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

Haematologica: the hematology journal

ISBN

—

ISSN

0390-6078

e-ISSN

—

Počet stran výsledku

2

Strana od-do

—

Název nakladatele

Fondazione Ferrata Storti

Místo vydání

Pavia

Místo konání akce

Barcelona, Spain

Datum konání akce

10. 6. 2010

Typ akce podle státní příslušnosti

EUR - Evropská akce

Kód UT WoS článku

000279051301143